Axovant Sciences Ltd (NASDAQ:AXON) was the recipient of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 3,010,456 shares, a drop of 31.3% from the November 15th total of 4,379,298 shares. Approximately 9.4% of the company’s stock are sold short. Based on an average daily volume of 745,858 shares, the short-interest ratio is currently 4.0 days.

Institutional investors and hedge funds have recently made changes to their positions in the business. Federated Investors Inc. PA purchased a new stake in Axovant Sciences during the 2nd quarter valued at $1,408,000. Lord Abbett & CO. LLC purchased a new stake in Axovant Sciences during the 2nd quarter valued at $696,000. Bank of New York Mellon Corp raised its stake in Axovant Sciences by 27.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 102,664 shares of the biotechnology company’s stock valued at $2,380,000 after buying an additional 21,801 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in Axovant Sciences during the 2nd quarter valued at $47,854,000. Finally, Tocqueville Asset Management L.P. purchased a new stake in Axovant Sciences during the 2nd quarter valued at $375,000. Institutional investors and hedge funds own 96.93% of the company’s stock.

Shares of Axovant Sciences (AXON) opened at $5.45 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94. Axovant Sciences has a 12 month low of $4.60 and a 12 month high of $27.98.

A number of equities analysts recently weighed in on the stock. Oppenheimer restated a “buy” rating and issued a $30.00 price objective on shares of Axovant Sciences in a report on Monday, September 25th. Jefferies Group set a $40.00 price objective on shares of Axovant Sciences and gave the stock a “buy” rating in a report on Friday, August 25th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Axovant Sciences in a report on Wednesday, September 27th. BidaskClub upgraded shares of Axovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, October 5th. Finally, Robert W. Baird restated a “hold” rating and issued a $6.00 price objective on shares of Axovant Sciences in a report on Wednesday, November 1st. Four analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. Axovant Sciences currently has an average rating of “Hold” and an average target price of $14.13.

ILLEGAL ACTIVITY WARNING: “Axovant Sciences Ltd (AXON) Sees Large Decrease in Short Interest” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/15/axovant-sciences-ltd-axon-sees-large-decrease-in-short-interest.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.